HALO develops novel oncology treatments targeting tumors and offers a health care technology platform that provides subcutaneous drug delivery. It recently won a patent approval for its Enhanze product, after which the company raised its full-year 2024 revenue guidance range to a top end of just more than $1 billion. As for earnings, the company showed a 21% increase in first-quarter revenue and a huge jump of 94% in net income. Investors should also like the firm’s plans to buy back up to $750 million in shares. It’s no wonder HALO shares are up 42% this year – and they could rise more. MAPsignals data shows how Big Money investors are betting heavily on the forward picture of the stock. Halozyme Shares Under Accumulation Institutional volumes reveal plenty. Recently, HALO has enjoyed strong investor demand, which we believe to be institutional support. Each green bar signals unusually large volumes in HALO shares. They reflect our proprietary inflow signal, pushing the stock higher: Source: www.mapsignals.com Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Halozyme. Halozyme Fundamental Analysis Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, HALO has had strong sales and earnings growth: 3-year sales growth rate (+46.7%) 3-year earnings growth rate (+66.1%) Source: FactSet Also, EPS is estimated to ramp higher this year by +24%. Now it makes sense why the stock has been powering to new heights. HALO has a track record of strong financial performance. Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term. Halozyme has been a top-rated stock at MAPsignals. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis. It’s made the rare Top 20 report multiple times in the last year. The blue bars below show when HALO was a top pick…making the share price rise higher: Source: www.mapsignals.com Tracking unusual volumes reveals the power of money flows. This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward. Halozyme Price Prediction The HALO rally isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio. Disclosure: the author holds no position in HALO at the time of publication. If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level, learn more about the MAPsignals process here. This article was originally posted on FX Empire More From FXEMPIRE: USD/JPY Forecast – US Dollar Gets Hammered After CPI Camtek Shares Rise on Big Sales, Stellar Earnings AUD/USD Forecast – Aussie Continues to Look Supported During Pullback AUD/USD Forecast – Aussie Dollar Continues to Threaten a Move Higher USD/JPY Weekly Price Forecast – US Dollar Continues to Look Bullish Is Gold Price Dropping?
Big Money Eyes Halozyme for Strong Growth
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...